5 Key Takeaways

• 1

  The IDSA updated its guidance on antimicrobial-resistant gram-negative infections, addressing six major pathogen groups.

• 2

  The guidance emphasizes the importance of susceptibility testing and reassessing treatment based on the organism's susceptibility profile.

• 3

  Preferred therapies vary by resistance mechanism, with carbapenems recommended for invasive ESBL-E infections outside the urinary tract.

• 4

  Newer beta-lactam agents are suggested for difficult-to-treat infections, with specific preferences based on infection type and resistance.

• 5

  The guidance aims to assist clinicians in making informed treatment decisions amid evolving antimicrobial resistance.